Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
0.134
-0.031 (-18.96%)
At close: Nov 22, 2024, 4:00 PM
0.135
+0.001 (0.60%)
After-hours: Nov 22, 2024, 7:44 PM EST
Citius Pharmaceuticals Employees
Citius Pharmaceuticals had 22 employees as of September 30, 2023. The number of employees increased by 1 or 4.76% compared to the previous year.
Employees
22
Change (1Y)
1
Growth (1Y)
4.76%
Revenue / Employee
n/a
Profits / Employee
-$1,807,516
Market Cap
25.85M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| DarioHealth | 294 |
| Athira Pharma | 67 |
| HCW Biologics | 45 |
| Equillium | 44 |
| Inspira Technologies Oxy B.H.N. | 42 |
| NEXGEL | 19 |
| GeoVax Labs | 17 |
| Ocean Biomedical | 9 |
CTXR News
- 18 hours ago - Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split - PRNewsWire
- 4 days ago - Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - PRNewsWire
- 7 days ago - Citius Pharmaceuticals Announces $3 Million Registered Direct Offering - PRNewsWire
- 11 days ago - Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors - PRNewsWire
- 2 months ago - Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - PRNewsWire
- 2 months ago - Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - PRNewsWire
- 3 months ago - Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - PRNewsWire
- 3 months ago - Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - PRNewsWire